Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study

American Journal of Ophthalmology

Volumn 158, Issue 5, 2014, Pages 1032-1038.e2

  Ogura, Yuichiro ^a   Roider, Johann ^b   Korobelnik, Jean François ^c,d,e   Holz, Frank G ^f   Simader, Christian ^g   Schmidt Erfurth, Ursula ^g   Vitti, Robert ^h   Berliner, Alyson J ^h   Hiemeyer, Florian ⁱ   Stemper, Brigitte ^i,j   Zeitz, Oliver ^i,k   Sandbrink, Rupert ^i,l  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF KIEL   (Germany)

^c HÔPITAL PELLEGRIN   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSERM   (France)

^f UNIVERSITY OF BONN   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h REGENERON PHARMACEUTICALS INC   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EVALUATION STUDY; FAINTNESS; GLAUCOMA; HUMAN; HUMERUS FRACTURE; IISCHEMIA; IRIS DISEASE; MACULAR EDEMA; MACULAR FIBROSIS; MACULAR ISCHEMIA; MAJOR CLINICAL STUDY; OCULAR FIBROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; RHINOPHARYNGITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNILATERAL BLINDNESS; VISUAL DISORDER; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; FEMALE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINAL VEIN OCCLUSION; TIME; VISUAL ACUITY;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84908658307     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.07.027     Document Type: Article

References (15)

1. T.Y. Wong, and I.U. Scott Clinical practice. Retinal-vein occlusion N Engl J Med 363 22 2010 2135 2144
2. R. Channa, M. Smith, and P.A. Campochiaro Treatment of macular edema due to retinal vein occlusions Clin Ophthalmol 5 2011 705 713
3. J.W. Miller, J. Le Couter, E.C. Strauss, and N. Ferrara Vascular endothelial growth factor A in intraocular vascular disease Ophthalmology 120 1 2013 106 114
4. H. Noma, H. Funatsu, T. Mimura, S. Eguchi, and K. Shimada Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion Br J Ophthalmol 95 6 2011 788 792
5. D.M. Brown, P.A. Campochiaro, and R.P. Singh Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 6 2010 1124 1133.e1121
6. P.A. Campochiaro, D.M. Brown, and C.C. Awh Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 10 2011 2041 2049
7. D. Boyer, J. Heier, and D.M. Brown Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study Ophthalmology 119 5 2012 1024 1032
8. D.M. Brown, J.S. Heier, and W.L. Clark Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study Am J Ophthalmol 155 3 2013 429 437.e427
9. F.G. Holz, J. Roider, and Y. Ogura VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 97 3 2013 278 284
10. J.F. Korobelnik, F.G. Holz, and J. Roider Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study Ophthalmology 121 1 2014 202 208
11. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 17 2002 11393 11398
12. J.A. Dixon, S.C. Oliver, J.L. Olson, and N. Mandava VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 10 2009 1573 1580
13. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 12 2012 2537 2548
14. J.S. Heier, W.L. Clark, and D.S. Boyer Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study Ophthalmology 121 7 2014 1414 1420.e1
15. J.S. Heier, P.A. Campochiaro, and L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 4 2012 802 809